Profilo
James Smith served as Vice President of Corporate Communications at YM BioSciences, Inc. from 2011 to 2014.
He then worked as Vice President of Business Development at Sierra Oncology, Inc. from 2014 to 2022.
Prior to that, he was Vice President of Corporate Development at SQI Diagnostics, Inc. Mr. Smith received his undergraduate and graduate degrees from Queen's University and an MBA from LaTrobe University.
Precedenti posizioni note di James Smith
| Società | Posizione | Fine |
|---|---|---|
| SIERRA ONCOLOGY, INC. | Contatto Relazioni con gli Investitori | 01/12/2020 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Contatto Relazioni con gli Investitori | 01/01/2014 |
| SQI DIAGNOSTICS INC. | Corporate Officer/Principal | - |
Formazione di James Smith
| Queen's University | Graduate Degree |
| LaTrobe University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SQI DIAGNOSTICS INC. | Health Technology |
| Aziende private | 2 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
- Borsa valori
- Insiders
- James Smith
